World

Oxford scientists expect Covid-19 vaccine data by Christmas

PTI London | Updated on November 20, 2020 Published on November 20, 2020

Phase-III trials of the vaccine are accumulating data needed to report results amid a surge of the pandemic

University of Oxford scientists expect to report results from the late-stage trials of their Covid-19 vaccine by Christmas, a key researcher said on Thursday as he discussed the team’s latest findings.

Andrew Pollard, an expert in pediatric infection and immunity at Oxford, said research was slowed by low infection rates over the summer, but the Phase-III trials are now accumulating the data needed to report results as a renewed surge of the pandemic hits countries around the world. Oxford is developing its vaccine in conjunction with drugmaker AstraZeneca.

“I think we’re getting close, and it’s definitely going to be before Christmas based on the progress,” Pollard said in an interview with the BBC.

Two other drugmakers, Pfizer and Moderna, this week reported preliminary results from late-stage trials showing that their Covid-19 vaccines were almost 95 per cent effective.

Pollard said there is no competition between the various research teams, because several vaccines will be needed to bring the global pandemic under control and allow life to return to normal.

ALSO READ: Oxford-AstraZeneca vaccine is safe for older age groups: Study

Long trek ahead

Despite recent progress, Pollard said the world is still in the early stages of the effort to protect people against Covid-19. Even after vaccines are approved by regulators, drugmakers and public health officials still face the task of producing billions of doses and administering them to people around the world, he said.

“I think we’re still at the bottom of that mountain in some ways,” he said.

“We’ve done the route into the bottom of the mountain, the long trek to get to the start. Now we’ve got to get the data about the vaccines in front of regulators for them to scrutinise it and approve the first vaccines. And then we’ve got that huge effort to climb up to the top where we’ve got a vast majority of those who are at risk vaccinated.”

ALSO READ: Covid-19 immunity may last for decades, study reveals

 

Follow us on Telegram, Facebook, Twitter, Instagram, YouTube and Linkedin. You can also download our Android App or IOS App.

Published on November 20, 2020
  1. Comments will be moderated by The Hindu Business Line editorial team.
  2. Comments that are abusive, personal, incendiary or irrelevant cannot be published.
  3. Please write complete sentences. Do not type comments in all capital letters, or in all lower case letters, or using abbreviated text. (example: u cannot substitute for you, d is not 'the', n is not 'and').
  4. We may remove hyperlinks within comments.
  5. Please use a genuine email ID and provide your name, to avoid rejection.